Volume 8, Issue 5, Pages (September 2014)

Slides:



Advertisements
Similar presentations
Figure 1. Inhibition of GSK3β reduces MiR biogenesis through repression of pri-MiR processing. (A) qRT-PCR analysis of miR-27a, miR-23a, miR-24, miR-141.
Advertisements

Volume 133, Issue 1, Pages (July 2007)
Cell Physiol Biochem 2017;44:1867– DOI: /
Mira Park, Ph. D. , Dae-Shik Suh, M. D. , Kangseok Lee, Ph. D
DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,
Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP  Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.
Volume 50, Issue 6, Pages (June 2013)
Jeroen Witteveldt, Alasdair Ivens, Sara Macias  Cell Reports 
Volume 133, Issue 1, Pages (July 2007)
MicroRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7  Yixiong Lin, Jianjun Liu, Yuqi Huang,
Shitao Li, Lingyan Wang, Michael A. Berman, Ye Zhang, Martin E. Dorf 
Volume 21, Issue 5, Pages (October 2017)
Molecular Therapy - Nucleic Acids
RNF168 Promotes Noncanonical K27 Ubiquitination to Signal DNA Damage
Volume 6, Issue 5, Pages (March 2014)
Volume 6, Issue 1, Pages (January 2014)
Volume 5, Issue 6, Pages (December 2013)
Volume 53, Issue 5, Pages (March 2014)
Feng Zhang, Jiazhong Shi, Chunjing Bian, Xiaochun Yu  Cell Reports 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 19, Issue 11, Pages (June 2017)
Volume 17, Issue 5, Pages (October 2016)
Wenqi Wang, Nan Li, Xu Li, My Kim Tran, Xin Han, Junjie Chen 
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2  Ji-guang Zhang,
Volume 130, Issue 4, Pages (August 2007)
Volume 23, Issue 3, Pages (February 2013)
Volume 25, Issue 3, Pages (February 2015)
Volume 15, Issue 4, Pages (April 2016)
Slicing-Independent RISC Activation Requires the Argonaute PAZ Domain
Volume 3, Issue 6, Pages (June 2013)
MiR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling  Hua Jin, Song Luo, Yun Wang, Chang Liu, Zhenghao.
Volume 6, Issue 1, Pages (January 2014)
Volume 13, Issue 1, Pages (January 2008)
Volume 66, Issue 4, Pages e5 (May 2017)
Promotion Effects of miR-375 on the Osteogenic Differentiation of Human Adipose- Derived Mesenchymal Stem Cells  Si Chen, Yunfei Zheng, Shan Zhang, Lingfei.
Kun-Peng Zhu, Xiao-Long Ma, Chun-Lin Zhang  Molecular Therapy 
Volume 39, Issue 3, Pages (August 2010)
ADAR Regulates RNA Editing, Transcript Stability, and Gene Expression
A Critical Role for Noncoding 5S rRNA in Regulating Mdmx Stability
Molecular Therapy - Nucleic Acids
Volume 59, Issue 6, Pages (September 2015)
Yi Tang, Jianyuan Luo, Wenzhu Zhang, Wei Gu  Molecular Cell 
Volume 5, Issue 3, Pages (November 2013)
Autoantigen La Promotes Efficient RNAi, Antiviral Response, and Transposon Silencing by Facilitating Multiple-Turnover RISC Catalysis  Ying Liu, Huiling.
Shrimp miR-34 from Shrimp Stress Response to Virus Infection Suppresses Tumorigenesis of Breast Cancer  Yalei Cui, Xiaoyuan Yang, Xiaobo Zhang  Molecular.
Jeroen Witteveldt, Alasdair Ivens, Sara Macias  Cell Reports 
Volume 21, Issue 6, Pages (November 2017)
Volume 28, Issue 5, Pages (March 2014)
Volume 22, Issue 2, Pages (January 2018)
Volume 23, Issue 5, Pages (May 2013)
Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation
Volume 25, Issue 5, Pages (March 2007)
Dan Yu, Rongdiao Liu, Geng Yang, Qiang Zhou  Cell Reports 
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Volume 5, Issue 6, Pages (December 2013)
The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2  Cheng-Cao Sun, Ling Zhang, Guang.
Volume 23, Issue 4, Pages (April 2015)
MicroRNA-125b Promotes Hepatic Stellate Cell Activation and Liver Fibrosis by Activating RhoA Signaling  Kai You, Song-Yang Li, Jiao Gong, Jian-Hong Fang,
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Volume 10, Issue 4, Pages (April 2017)
Molecular Therapy - Nucleic Acids
Volume 62, Issue 3, Pages (May 2016)
Volume 2, Issue 4, Pages (October 2012)
Volume 26, Issue 9, Pages (September 2018)
Volume 53, Issue 5, Pages (March 2014)
Volume 11, Issue 3, Pages (September 2012)
CDK Phosphorylation of Translation Initiation Factors Couples Protein Translation with Cell-Cycle Transition  Tai An, Yi Liu, Stéphane Gourguechon, Ching.
Volume 41, Issue 4, Pages (February 2011)
Volume 13, Issue 1, Pages (October 2015)
Presentation transcript:

Volume 8, Issue 5, Pages 1447-1460 (September 2014) The RNA-Binding Protein DDX1 Promotes Primary MicroRNA Maturation and Inhibits Ovarian Tumor Progression  Cecil Han, Yunhua Liu, Guohui Wan, Hyun Jin Choi, Luqing Zhao, Cristina Ivan, Xiaoming He, Anil K. Sood, Xinna Zhang, Xiongbin Lu  Cell Reports  Volume 8, Issue 5, Pages 1447-1460 (September 2014) DOI: 10.1016/j.celrep.2014.07.058 Copyright © 2014 The Authors Terms and Conditions

Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions

Figure 1 Interaction of DDX1 with the Drosha Microprocessor (A) Interaction between endogenous DDX1 and Drosha/DGCR8. Immunoprecipitation (IP) and western blotting analyses were performed using indicated antibodies. Normal immunoglobulin G (IgG) was used as a negative control for IP. RNA-binding proteins ADAR and p84 were used as negative controls for the Drosha-binding proteins. WCL, whole-cell lysate. (B) RNA-independent interaction between DDX1 and Drosha. DDX1 immunoprecipitates were treated with RNase A (10 U) or RNase V1 (10 U) and separated to supernatant and bead-bound fractions for western blotting analyses. (C) Schematic representation of DDX1 domains (upper panel) and the interaction between Drosha and truncated forms of DDX1 (bottom panel). GST-fused DDX1 proteins were immobilized on glutathione Sepharose beads and mixed with the lysate of HEK293T cells expressing Drosha-FLAG. (D) Depletion of DDX1 inhibits the expression of a subset of miRNAs. Total RNAs from control and DDX1 knockdown (KD) were subject to global miRNA-profiling analyses using qPCR miRNA microarray. Green and red on the heatmap indicate a decrease and increase of miRNA level, respectively, and color intensities correspond to relative signal levels. A total of 36 miRNAs with over 2-fold reduction in the DDX1-knockdown cells were identified as DDX1-dependent miRNAs. The DDX1-dependent miRNAs in the miR-200 family and the eight-miRNA signature for the mesenchymal subtype of ovarian cancer are marked with an asterisk (∗). See also Figure S1. Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions

Figure 2 Posttranscriptional Regulation of miRNA Expression by DDX1 (A) Levels of primary or mature forms of the DDX1-dependent miRNAs in control and DDX1-knockdown U2OS cells. (B) Levels of primary or mature forms of the DDX1-dependent miRNAs in control and DDX1-overexpressing U2OS cells. In both (A) and (B), miR-21 was used as a DDX1-independent control. (C) Levels of DDX1-dependent miRNAs in control or DDX1-knockdown cell lines as indicated. HeyA8 and SKOV3 are human ovarian cancer cell lines, and IG10 is a mouse ovarian cancer cell line. HCT116p53+/+ and HCT116p53−/− are a pair of isogenic colorectal cancer cell lines. U6 RNA was used for normalization in qPCR analyses, and miR-21 was used as a DDX1-independent miRNA control. Error bars represent the mean ± SD: ∗p < 0.05; ∗∗p < 0.001. See also Figure S2. Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions

Figure 3 DDX1 Recruits Target Pri-miRNAs to the Drosha Microprocessor and Promotes Their Processing (A) RIP analysis reveals that primary forms of DDX1-dependent miRNAs are physically associated with DDX1 in U2OS cells. The DDX1-bound pri-miRNAs were analyzed by qRT-PCR. Control IgG was used as a negative control (∗p < 0.05; ∗∗p < 0.01). (B) Interaction between pri-miRNAs and DDX1 determined by the MS2-TRAP assay. Schematic illustration of MS2-TRAP assay is shown at the top. MS2-tagged pri-miRNAs and their associated protein complexes were pulled down by anti-GST beads, and proteins were detected by western blotting. (C) RIP analysis of the Drosha-interacting pri-miRNAs in control and DDX1-knockdown cells (∗∗p < 0.01). Pri-miR-21 was used as a DDX1-independent control. (D and E) Pri-miRNA-processing activity in DDX1-knockdown (D) and -overexpressing (E) cells. The firefly luciferase signals are normalized by internal control Renilla luciferase readings, and relative processing activity was shown as fold changes (∗∗p < 0.01). Error bars represent the mean ± SD in this figure. See also Figures S3 and S4. Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions

Figure 4 DNA Damage-Induced Expression of DDX1-Dependent miRNAs (A) DDX1 is translocalized to the DNA damage foci. U2OS cells were treated with NCS (500 ng/ml) for 30 min and analyzed by immunostaining using anti-γ-H2AX and anti-DDX1 antibodies. DAPI was used for nucleus staining. Scale bars, 10 μm. (B) Expression of DDX1-dependent miRNAs is induced after DNA damage. Total RNAs were purified from the control (Ctrl) and DDX1-knockdown cells treated with or without NCS (500 ng/ml, 6 hr) and subject to global miRNA expression-profiling analyses using human miRNA qPCR microarray. miR-218 and miR-21 were used as DDX1-independent controls. miR-21 is induced after DNA damage. (C) DNA damage induction of DDX1-dependent (DDX1-KD/control <0.50) and DDX1-independent (DDX1-KD/control >0.50) miRNAs. (D) Levels of miR-200a/miR-200b/miR-200c were induced after NCS (500 ng/ml) treatment in control U2OS cells, but not in the DDX1-knockdown U2OS cells. miR-218 and miR-21 were used as DDX1-independent controls. Error bars represent the mean ± SD. See also Figure S5. Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions

Figure 5 ATM Phosphorylation Facilitates DDX1 in Pri-miRNA Processing (A) Two putative ATM phosphorylation sites are conserved in mammalian DDX1 genes. Phosphorylation-deficient mutant (2MT) was generated by mutating serine (Ser) to alanine (Ala) on both sites. (B) WT DDX1, but not the 2MT, is phosphorylated by the ATM kinase. Purified WT or mutant DDX1 proteins were incubated with immunopurified ATM in a kinase buffer containing 32P-ATP. (C) Interaction between DDX1 and Drosha was unchanged after DNA damage. U2OS cells were treated with 500 ng/ml NCS for 4 hr, and cell lysates were harvested for immunoprecipitation and western blotting (WB) analyses. (D) DNA damage treatment enhances the interaction of DDX1 with pri-miR-200a/pri-miR-200b. RIP assays were performed using anti-DDX1 antibody and lysates of U2OS cells treated with or without NCS (∗∗p < 0.01). (E) DNA damage-induced expression of miR-200a/miR-200b is dependent on ATM. ATM activity is inhibited by CGK733 (10 μM) (∗p < 0.05). ATM IN, ATM inhibition. (F) Overexpression of WT DDX1, but not the phosphorylation-deficient DDX1, restored the induction of miR-200a/miR-200b expression after DNA damage. miR-218 was used as a negative control. Error bars represent the mean ± SD in this figure. See also Figure S6. Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions

Figure 6 Silencing DDX1 Promotes Ovarian Tumor Cell Invasion In Vitro and Ovarian Tumor Progression In Vivo (A) Knockdown of DDX1 promotes ovarian tumor cell invasion. Matrigel invasion assays were performed on control or DDX1-knockdown SKOV3 and IG10 cells. The average number of invasive cells per field of view (FOV) is presented (∗∗p < 0.001). (B) Knockdown of DDX1 promotes IG10 syngeneic tumor growth. Control and DDX1-knockdown IG10 cells expressing firefly luciferase were injected intraperitoneally into female C57BL/6N mice. Shown are the representative luciferase images of ovarian tumors. (C) Quantification of tumor weights and tumor nodules in mice (n = 10 for each group). Error bar represents the mean ± SEM. (D) Representative images of tumor nodules and metastases in the mice carrying syngeneic ovarian tumors derived from control and DDX1-knockdown IG10 cells. Shown here are tumor mass in omentum of a control tumor (I) and tumor mass in omentum (II), perihepatic area (III), mesentery (IV), lymph nodes (V), and diaphragm (VI) of DDX1-knockdown tumors. (E) Frequency of metastases to distant sites (mesentery, omentum, diaphragm, perihepatic, and other sites). Other sites include paraaortic lymph nodes, kidney, and ovary. (F) Levels of miR-200a/miR-200b and their targets ZEB1 and ZEB2 in control and DDX-silenced tumors. Error bars represent the mean ± SD: ∗p < 0.05. (G) Immunohistochemical (IHC) analysis of ZEB1, E-Cadherin, and Vimentin in control and DDX1-knockdown ovarian tumors. Scale bars, 30 μm. Relative levels of ZEB1, E-Cadherin, and Vimentin are shown in the graph (see Experimental Procedures for IHC score; ∗p < 0.05). Error bars represent the mean ± SD. H&E, hematoxylin and eosin staining. Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions

Figure 7 DDX1 Levels Are Positively Correlated with Clinical Outcome in Patients with Cancer (A) Low levels of DDX1 are associated with poor overall survival in patients with ovarian tumors. Kaplan-Meyer plots for overall survival (OS) of patients with ovarian serous adenocarcinoma (OV) are shown. The entire population (n = 388) was randomly split into training/validation cohorts (two-thirds and one-third), and a correlation with the survival was determined as described in Supplemental Experimental Procedures. An analysis of the validation cohort (n = 129) is shown here. RNASeq, RNA sequencing; pt, patients. (B) Low levels of DDX1 are associated with poor overall survival in patients with kidney renal clear cell carcinoma (KIRC). An analysis of the validation cohort (n = 156) is shown here. (C) Relative expression levels of miR-200a (p = 0.006) and miR-200c (p = 0.04) in the DDX1-low and -high groups from the validation cohort of ovarian serous adenocarcinomas. Error bars represent the mean ± SD. (D) Immunohistochemical analysis and in situ hybridization of DDX1 and miR-200a in human ovarian tumor tissue microarray. Scale bars, 100 μm. See also Figure S7. Cell Reports 2014 8, 1447-1460DOI: (10.1016/j.celrep.2014.07.058) Copyright © 2014 The Authors Terms and Conditions